Metabolomic analysis of human plasma from haemodialysis patients
Metabolomic analysis of human plasma from haemodialysis patients
复制标题
DOI：
10.1111/j.1365-2362.2010.02398.x
复制
发表时间：
2011-03-01
影响因子：
5.5
通讯作者：
Tanaka, Noriaki
中科院分区：
文献类型：
--
作者：
Sato, Emiko;Kohno, Masahiro;Tanaka, Noriaki
背景尿素和肌酐是广泛应用的疾病生物标志物.然而，这些参数作为标记物受到批评，原因有几个。因此，在本发明中，我们进行了这项研究，以确定新的生物标志物，可以作为替代尿素和肌酐，以估计适当的透析剂量通过代谢组学分析的血浆样本，从病人接受血液透析。材料和方法液相色谱-电喷雾电离（ESI）-飞行时间质谱（MS）被用来分析低分子量分子存在于血浆样本中的10例终末期肾病患者。结果血液透析后血浆中54个峰的相对含量与透析前相比明显降低（P < 0.0 5），而透析后血浆中54个峰的相对含量与透析前相比无显著性差异（P> 0.0 5）。将候选生物标志物分配到三个组。血液透析后，A组分子完全改善，但差异较大，B组分子部分改善，但差异较大，C组分子部分改善，但差异较小。结论1-甲基肌苷和m/z分别为257 center dot 1033和413 center dot 1359的两种未知分子可作为估计血液透析剂量的有效候选生物标志物。这需要在前瞻性研究中得到证实。
P>BackgroundUrea and creatinine are widely used as biomarkers for disease. However, these parameters have been criticized as markers for several reasons. Thus, we conducted this study to identify novel biomarkers that can be used as alternatives to urea and creatinine to estimate the adequate dialysis dose by metabolomic analyses of plasma samples from patients undergoing haemodialysis.Material and methodsLiquid chromatography-electrospray ionization (ESI)-time-of-flight mass spectrometry (MS) was used to analyse low molecular weight molecules present in the plasma samples of 10 patients with end-stage renal disease (ESRD) who were being treated with haemodialysis, and in 16 healthy subjects.ResultsIn plasma samples obtained after haemodialysis, the relative quantities of 54 peaks were significantly (P < 0 center dot 05) decreased when compared with those in the plasma before haemodialysis. The candidate biomarkers were allocated to three groups. Molecules in Group A improved completely with a large variance, molecules in Group B improved partially but with a large variance, and molecules in Group C improved partially with low variance after haemodialysis. Small cohort validation study consisting of the patients with ESRD undergoing haemodialysis indicates that three candidate biomarkers in Group C would be a very useful marker to estimate adequate haemodialysis dose.Conclusions1-Methylinosine and two unknown molecules whose m/z at ESI-positive mode are 257 center dot 1033 and 413 center dot 1359 were found as effective candidate biomarkers to estimate adequate haemodialysis dose, which has to be confirmed in prospective studies.